Early diagnosis in transthyretin cardiac amyloidosis (ATTR CM) matters more than ever. Adith Arun talks with Dr. Ahmad Masri about key findings from the ATTRIBUTE CM phase 3 trial on acoramidis, what recurrent event analyses reveal, and why delays in suspicion, diagnosis, or treatment can meaningfully impact outcomes. They also explore challenges in clinical pathways, updates in the therapeutic landscape, and the biggest unmet needs as patients live longer with disease directed therapy.